Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B
- PMID: 15944649
- DOI: 10.1038/sj.jcbfm.9600146
Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B
Abstract
A valid quantitative imaging method for the measurement of amyloid deposition in humans could improve Alzheimer's disease (AD) diagnosis and antiamyloid therapy assessment. Our group developed Pittsburgh Compound-B (PIB), an amyloid-binding radiotracer, for positron emission tomography (PET). The current study was aimed to further validate PIB PET through quantitative imaging (arterial input) and inclusion of subjects with mild cognitive impairment (MCI). Pittsburgh Compound-B studies were performed in five AD, five MCI, and five control subjects and five subjects were retested within 20 days. Magnetic resonance images were acquired for partial volume correction and region-of-interest definition (e.g., posterior cingulate: PCG; cerebellum: CER). Data were analyzed using compartmental and graphical approaches. Regional distribution volume (DV) values were normalized to the reference region (CER) to yield DV ratios (DVRs). Good agreement was observed between compartmental and Logan DVR values (e.g., PCG: r=0.89, slope=0.91); the Logan results were less variable. Nonspecific PIB retention was similar across subjects (n=15, Logan CER DV: 3.63+/-0.48). Greater retention was observed in AD cortical areas, relative to controls (P<0.05). The PIB retention in MCI subjects appeared either 'AD-like' or 'control-like'. The mean test/retest variation was approximately 6% in primary areas-of-interest. The Logan analysis was the method-of-choice for the PIB PET data as it proved stable, valid, and promising for future larger studies and voxel-based statistical analyses. This study also showed that it is feasible to perform quantitative PIB PET imaging studies that are needed to validate simpler methods for routine use across the AD disease spectrum.
Similar articles
-
Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.J Nucl Med. 2005 Dec;46(12):1959-72. J Nucl Med. 2005. PMID: 16330558
-
Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease.Neuroimage. 2007 Jun;36(2):298-312. doi: 10.1016/j.neuroimage.2007.03.004. Epub 2007 Mar 16. Neuroimage. 2007. PMID: 17449282 Free PMC article.
-
Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease.Neuroimage. 2006 Oct 15;33(1):94-102. doi: 10.1016/j.neuroimage.2006.05.063. Epub 2006 Aug 14. Neuroimage. 2006. PMID: 16905334
-
Relationship between memory performance and β-amyloid deposition at different stages of Alzheimer's disease.Neurodegener Dis. 2012;10(1-4):141-4. doi: 10.1159/000334295. Epub 2012 Feb 1. Neurodegener Dis. 2012. PMID: 22301812 Review.
-
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.Adv Pharmacol. 2012;64:27-81. doi: 10.1016/B978-0-12-394816-8.00002-7. Adv Pharmacol. 2012. PMID: 22840744 Free PMC article. Review.
Cited by
-
Traumatic brain injury and Alzheimer's Disease biomarkers: A systematic review of findings from amyloid and tau positron emission tomography (PET).medRxiv [Preprint]. 2023 Dec 1:2023.11.30.23298528. doi: 10.1101/2023.11.30.23298528. medRxiv. 2023. Update in: J Neurotrauma. 2024 Dec 6. doi: 10.1089/neu.2024.0055. PMID: 38077068 Free PMC article. Updated. Preprint.
-
Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.Acta Neuropathol. 2012 Mar;123(3):433-47. doi: 10.1007/s00401-012-0943-2. Epub 2012 Jan 24. Acta Neuropathol. 2012. PMID: 22271153 Free PMC article.
-
Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches.Neuroimage. 2013 May 1;71:207-15. doi: 10.1016/j.neuroimage.2013.01.015. Epub 2013 Jan 24. Neuroimage. 2013. PMID: 23353602 Free PMC article.
-
Effects of age and β-amyloid on cognitive changes in normal elderly people.Neurobiol Aging. 2012 Dec;33(12):2746-55. doi: 10.1016/j.neurobiolaging.2012.02.008. Epub 2012 Mar 17. Neurobiol Aging. 2012. PMID: 22429886 Free PMC article.
-
CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology.Nat Neurosci. 2013 Jul;16(7):848-50. doi: 10.1038/nn.3435. Epub 2013 May 23. Nat Neurosci. 2013. PMID: 23708142 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical